Tuesday, October 4, 2022


Biotechnology News Magazine

BioFluidica Announces $6 Million Series B2 Funding

To Support the Commercialization of its Liquid Biopsy Microfluidics Platform, the LiquidScan™, and the Development of its Advanced Handheld Covid-19 Detection Device for Consumer At-Home Testing

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BioFluidica, Inc., a biotechnology company developing a diagnostic platform allowing for disease management and diagnosis, today announced that it has raised over $6 million in the initial closings of its Series B2 financing.

Additional closings in this targeted $10 million financing are anticipated following successful completion of development milestones relating to BioFluidica’s handheld infectious disease detection device using nanofluidics for ultrafast high-sensitivity detection of virus particles. The funding round was led by BioFluidica’s existing investor base, with participation from new investors.

“We are grateful for the continuing financial support of our existing investors and welcome our new investors,” said CEO Dr. Rolf Muller. He added, “This funding will allow BioFluidica to expand the commercialization of its LiquidScan™ instruments and consumables, for the isolation and analysis of all Liquid Biopsy biomarkers including cells, exosomes & cell free nucleotides on one platform. This investment also supplements funding from the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) initiative to advance the commercial development of our handheld device for infectious disease testing with its first Point-Of-Care device for low-cost, high-sensitivity Covid-detection at-home.”

Dr. Steven Soper, Foundation Distinguished Professor of Chemistry, Mechanical Engineering, Bioengineering, and Cancer Biology at the Kansas University as well as BioFluidica’s cofounder added “This funding will bring the advantage of advanced micro- and nanotechnology to patients worldwide. Specifically, innovative tools will evolve that can revolutionize healthcare, especially for cancer patients, through the use of liquid biopsies. In addition, new at-home tests will be generated that can assist in improving the management of current and future issues with viral infections.”




Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine